Mortality and Neurologic Outcomes in Rapid vs. Slow Hyponatremia Correction

CompletedOBSERVATIONAL
Enrollment

2,037

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

April 30, 2024

Study Completion Date

May 1, 2024

Conditions
HyponatremiaHospitalisationMortalitySEVERE HYPONATREMIA
Interventions
OTHER

Rapid sodium correction

"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \< 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."

OTHER

Slow sodium correction

"This study focuses on the exposure to different sodium correction rates in patients with severe hyponatremia (serum sodium ≤ 120 mEq/L) rather than an active intervention. The two key groups are defined by their rate of sodium correction during the first 24 hours of hospitalization:~Rapid Sodium Correction: An increase in serum sodium of ≥ 8 mEq/L within 24 hours.~Slow Sodium Correction: An increase in serum sodium of \< 8 mEq/L within 24 hours.~The primary objective is to assess the association between these exposure rates and clinical outcomes, including in-hospital mortality, 30-day mortality, and the incidence of osmotic demyelination syndrome (ODS). This study differs from others by using a large, retrospective cohort of patients treated in a real-world clinical setting, spanning 13 years (2010-2023), and applying robust statistical adjustments such as propensity score analysis to control for confounders."

Trial Locations (1)

C1199ABB

Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires

All Listed Sponsors
collaborator

University of California, Irvine

OTHER

collaborator

Hospital Privado de Comunidad de Mar del Plata

OTHER

collaborator

University of Pittsburgh

OTHER

lead

Hospital Italiano de Buenos Aires

OTHER

NCT06675591 - Mortality and Neurologic Outcomes in Rapid vs. Slow Hyponatremia Correction | Biotech Hunter | Biotech Hunter